Enliven Positive Initial Phase 1b Data for ELVN-001 in CML, 2026 Clinical Milestones

 Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts

ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels evaluated, consistent with previously reported data

Data further reinforce ELVN-001's positioning as the potentially best-in-class active-site TKI in CML

Multiple key data, regulatory and operational catalysts expected in 2026

https://www.prnewswire.com/news-releases/enliven-reports-positive-initial-phase-1b-data-for-elvn-001-in-cml-and-outlines-2026-clinical-milestones-302655863.html